Efficacy of HoLEP and PVP for BPH (randomized controlled trial)

Efficacy of HoLEP and PVP for BPH (randomized controlled trial) - Efficacy of HoLEP and PVP for BPH (randomized controlled trial)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013049

Enrollment

Registered

2014-03-01

Start date

2014-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign prostatic hyperplasia

Interventions

HoLEP PVP

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: The patients who had recieved alfa 1 blocker for BPH. I-PSS total score higher than 8 and QOL score higher than 3 Maximum urinary flow rate lower than 10ml/s Total prostate volume larger than 20ml

Exclusion criteria

Exclusion criteria: 1 Patients has organic disease other than BPH, that was prostate cancer,bladder tumor, bladder stone, prostatitis, urethral stenosis et al. 2 Patients were performed urological surgery before 6 months. 3 Patients have active urinary infection. 4 Patients has neurogenic bladder. 5 Patients has severe ischemic coronary disease, cerebrovascular accident, liver dysfunction, renal dysfunction. 6 Patients has hypotension. 7 Doctor has other patients deemed inappropriate

Design outcomes

Primary

Measure	Time frame
International Prostate Symptom Score Urinary flow rate Residual urine	—

Countries

Japan

Contacts

Public ContactKazuhiko fukumoto

Kawasaki medical school urology

urology@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026